Cagrilintide monograph

Cagrilintide

Overview

Cagrilintide is an investigational long-acting amylin analog developed for weight management and studied both as monotherapy and in combination with semaglutide (CagriSema). Current human data support meaningful appetite/weight reduction, but the evidence base is still limited and the drug is not established as an approved obesity therapy. Clinical utility is mainly in obesity/metabolic research, not bodybuilding performance.

Pharmacokinetics & Mechanism

• Class: Long-acting amylin analog peptide; investigational anti-obesity agent
• Mechanism of action: Cagrilintide is an amylin receptor agonist analog designed to reduce energy intake by increasing satiety and slowing gastric emptying, which lowers appetite and supports weight loss. Human outcome data are largely from obesity trials and combination-therapy studies rather than from an approved-label package insert, so detailed mechanistic labeling remains investigational.
• Target(s): Amylin receptor signaling pathways; likely amylin receptor complexes involving calcitonin receptor with receptor activity-modifying proteins (RAMPs). It is not a GLP-1 receptor agonist itself, but it is commonly paired with semaglutide in CagriSema.
• Route(s) of administration: Subcutaneous injection only in the studied clinical programs.
• Onset: Not well established in humans; appetite suppression is expected after subcutaneous dosing, but precise onset timing is not clearly established in the authoritative sources reviewed.
• Half-life: Not well established from the sources reviewed. ClinicalTrials.gov identifies ongoing PK studies of cagrilintide B and D with steady-state PK endpoints, but the extracted registry text did not provide a terminal half-life value. If community sources claim a specific weekly half-life, treat that as unverified until confirmed in a peer-reviewed PK publication.
• Metabolism / clearance: Not well established in the sources reviewed. Human clearance/metabolic pathways were not specified in the authoritative sources accessed here; current registry text only confirms that steady-state exposure and apparent clearance are being measured in ongoing studies.